Drotaverine to Shorten the Length of Labor

Labor Pain Clinical Trial

Official title:

Use of Antispasmodic Drotaverine to Shorten the Length of Labor in Nulliparous Women

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01639027
• Other study ID #: Drotaverine in labor
• Status: Completed
• Phase: Phase 2/Phase 3
• First received: July 9, 2012
• Last updated: January 17, 2013
• Start date: May 2012
• Est. completion date: January 2013

Study information

• Verified date: January 2013
• Source: Ain Shams Maternity Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Egypt: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

Reducing the length of labor is a highly desirable goal of intrapartum care, both from a perspective of maternal and fetal well-being, and for the providers of the birth services. Avoiding along, protracted labor entails shorter exposure to pain, anxiety and stress and would thus translate into a major improvement in maternal satisfaction with the childbirth experience.

Based on the premise that shortening the length of labor is beneficial, interventions aimed at accelerating the progression of labor have been introduced routinely as part of standard labor management and care throughout the 20th century. Certain labor accelerative procedures, such as amniotomy, became common practice and have been put to the acid test of randomized control trials to evaluate their efficacy. Use of anticholinergics/antispasmodics as a method of augmenting labor was first described in 1937 by Hirsch, who reported a decrease in labor length by two to four hours following Intrapartum administration of an atropine-like drug (Syntropan®)mainly among older nulliparas.

Drotaverine, an isoquinolone derivative is a superior smooth muscle relaxant which acts specifically on spastic sites and corrects the cAMP and calcium balance relieving smooth muscle spasm.

This inhibitory action is detected only in lower uterine segment during labor since muscle fibers in upper uterine segment are strongly affected by contractile effect of oxytocin. Use of drotaverine during pregnancy is free of any teratogenic and embryotoxic effects.

The Research question is: Does the use of antispasmodic Drotaverine shorten the duration of active first stage of labor in nulliparous women as compared to placebo?

Description:

Research question:

Does the use of antispasmodic Drotaverine shorten the duration of active first stage of labor in nulliparous women as compared to placebo?

Research hypothesis: the population means of the Drotaverine and placebo groups are equal regarding the duration of the first stage of labor.

Objectives:

The purpose of this study was to determine the effectiveness of Drotaverine for reducing the duration of labor for the context of contemporary practice, among nulliparous women managed according to a standard intrapartum protocol.

Study setting:

Patients will be recruited from women admitted in labor at the delivery unit of Ain Shams Maternity Hospital.

Study design:

This study is a phase II to III, intervention study- Randomized Controlled double blind study.

Procedure:

Every patient will be subjected to:

1. Complete history to exclude allergy to Drotaverine Hydrochloride and any contraindication for normal vaginal delivery.

2. General examination of the patients including (pulse, blood pressure, temperature).

3. Obstetric Abdominal examination including lie, presentation,station; fetal heart rate, uterine contraction, amount of liquor and to exclude multiple pregnancies.

4. Vaginal examination under aseptic conditions to assess cervical dilation, effacement, state of fetal membranes, presenting part,position of fetal head, color of liquor and pelvic adequacy.

5. Assessment of the frequency, duration of uterine contractions and monitoring of fetal wellbeing will be applied through CTG application on admission:

• CTG will be applied half an hour to all participants before starting any intervention.

1. If the contractions are not adequate:

• Patients with intact membranes → AROM will be done, reassessment after one hour. If still no adequate contraction, Oxytocin infusion will start (five I.U. Oxytocin in 500 cc ringer I.V. drip) by titration method until complete regulation of uterine contractions.

• Those with ruptured of membranes, the amniotic fluid color will be checked for any abnormalities and Oxytocin infusion will start (five I.U. Oxytocin in 500 cc ringer I.V. drip) by titration method until complete regulation of uterine contractions.

2. If the contractions are adequate: No interference will be done.

6. Each participant will randomly take a prefilled syringe with two milliliters of the study medication solution (either Drotaverine Hydrochloride or saline). Each participant will take the selected syringe slowly intravenously over two minutes.

7. Partographic representation of labor and duration of first stage to determine the primary end point of the study "duration of 1st stage".

8. Cervical effacement and dilatation in addition to station and position of fetal head will be recorded every two hours by vaginal examination.

9. Reassessment after four hours of the first dose:

A) If poor progress: Initially, exclude C.P.D. & uterine inertia.

• If there is an obvious cause:

• C.P.D.: Urgent C-section will be done.

• Uterine inertia: adjust the dose of Oxytocin I.V drip via titration method until complete regulation of uterine contraction.

• If there is no obvious cause:

• Another dose of the colorless solution will be given then reassessment after four hours, If no progress → re evaluation for final decision of mode of delivery.

B) If good progress: No interference will be done.

Outcome:

1. Primary outcomes:

1. The duration of the active first stage of labor(Partographic representation for cervical effacement and dilatation will be plotted for each participant).

2. Rate of cervical dilation (cm/h).

2. Secondary outcomes:

1. Effect on pain by using visual analogue scale once before and one hour after injection of solution. VAS will be done at 30, 60 and 120 minutes of the drug administration.

2. Mode of delivery.

3. APGAR score less than 7 at 1 and 5 minutes.

4. Maternal drug side effect will be recorded.

Randomization and Blinding:

Randomization will be achieved using a computer-generated randomization sequence. Allocation will be in a 1:1 ratio. Records of group allocation will be maintained by a resident physician "other than the researcher" whose responsibility will be randomization and drawing up the injection after dark sealing of the syringes with black opaque stickers to make the yellowish colored Drotaverine Hydrochloride (Do-Spa®) in-differentiable from the translucent saline solution.

This house officer has no direct involvement in the intrapartum decision making. Drotaverine Hydrochloride and saline injections will have an identical appearance. The midwives, the clinicians staffing labor and delivery and the patients could not distinguish the placebo from the active drug. The randomization list will be held in a secure box on the labor ward to ensure concealment of the allocation of intervention from those recruiting participants.

Data Collection:

Maternal characteristics and labor information will be prospectively collected in a computerized database that will be maintained with daily chart review by the researcher to ensure accuracy and to minimize missing data The primary end-point of this study will be the duration of the first stage of labor.The first stage encompasses the onset of active labor to complete cervical dilatation.

However, as women will be randomized at different dilatation levels, to allow meaningful comparison the dilatation rates (from administration of study drug

o full dilatation) will be calculated and will be used as the primary outcome measure.

Analysis:

Data analysis and reporting will strictly follow the recommendation of CONSORT 2010 For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (95% confidence interval).

For binary outcomes, presentation of both absolute risk difference and relative (Risk Ratio) effect sizes will be reported.

Ethical considerations

IRB approval:

The clinical research study will be conducted in accordance with the current IRB-approved clinical protocol; ICH GCP Guidelines; and relevant policies, requirements, and regulations of the Ain Shams University.

Consent procedure:

The investigator will make certain that an appropriate informed consent process is in place to ensure that potential research subjects, or their authorized representatives, are fully informed about the nature and objectives of the clinical study, the potential risks and benefits of study participation, and their rights as research subjects. The investigator will obtain written, signed informed consent of each subject, or the subject's authorized representative, prior to performing any study-specific procedures on the subject. The investigator will retain the original signed informed consent form.

Subject confidentiality:

All laboratory specimens, evaluation forms, reports, video recordings and other records that leave the site will not include unique personal data to maintain subject confidentiality.

Funding: Internal funding by using the Hospital resources.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 352
• Est. completion date: January 2013
• Est. primary completion date: December 2012
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• Women aged between 18 and less than 35 years.

• Primigravidae.

• Singleton pregnancy.

• Term gestation i.e., 37-42 weeks.

• Sure, reliable dates documented by ultrasound in the 1st half of pregnancy.

• Vertex presentation with occipito anterior position

• Regular uterine contractions at a rate of at least 3 to 4 contractions every 10 minutes, each contraction lasting for at least 40 seconds.

• Cervical dilatation of 3-5 cm.

• With or without rupture of membranes

• No evidence of maternal or fetal distress.

Exclusion Criteria:

• Cephalo-pelvic disproportion.

• Cervical surgery in the past or history of cervical injury.

• Patients on antihypertensive therapy.

• Known hypersensitivity to Drotaverine hydrochloride.

• If any other spasmolytic agent had been used within 48 hours.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Asphyxia Neonatorum
• Failure of Cervical Dilation as Antepartum Condition
• Labor Pain
• Mild Birth Asphyxia, APGAR 4-7
• Prolonged First Stage of Labor

Intervention

Drug:
• Drotaverine
40 mg Drotaverine hydrochloride (Do-Spa) IV injection at the start of the study and repeated every 2 hours up to a maximum 3 injections.
• Placebo
Women who will receive 2ml of normal physiological saline (0.9% sodium chloride) I.V at the start of the active phase of labor.

Locations

Country	Name	City	State
Egypt	Labor at the delivery unit of Ain Shams Maternity Hospital	Abbasiya	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
Ain Shams Maternity Hospital

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Duration of the active first stage of labor		12 hours	No
Secondary	Rate of cervical dilation (cm/h)		12 hours	No
Secondary	Effect on pain by using visual analogue scale		12 hours	No
Secondary	Mode of delivery		12 hours	No
Secondary	APGAR score less than 7 at 1 and 5 minutes		12 hours	Yes

External Links

•   Ain Shams University